The U.S. Food and Drug Administration (FDA) last month approved a rechargeable neurostimulator and a recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). Medtronic is marketing the products as Intellis™ and Vanta™, respectively. DPN is a debilitating and progressive neurological disorder that affects approximately 30% of people with diabetes,...
Endocrine research remains at the forefront of medical breakthroughs, which has led to cutting-edge treatment options, therapies, and products. From remarkable new treatments for acromegaly, thyroid eye disease, hypoglycemia, and diabetes to new devices aimed at glucose monitoring in adults and children, a mail-in semen analysis kit, and much more, Endocrine News takes a closer...
During insulin’s first century, treatments and resources for people with diabetes have steadily progressed. So, too, have relationships between the patient and the provider. A recent Endocrine Society-hosted roundtable highlighted this vital connection and how it has evolved through the decades. Leonard Thompson was 14 years old in 1922, and he was dying of type...Omitting Race from Kidney Function Equations Leads to More Accurate Results
At the end of September, a paper appeared in the New England Journal of Medicine that showed omitting race from equations for estimated glomerular filtration rate (eGFR) leads to more accurate results when determining kidney function. The researchers, led by Lesley Inker, MD, MS, director of the Kidney Function and Evaluation Center at Tufts Medical...
Since acromegaly is such a rare disorder, when an endocrinologist is presented with a potential case, the most accurate and complete data available would be a helpful tool. Endocrine News takes a closer look at how the Mexican Acromegaly Registry has helped endocrinologists address the issues patients with acromegaly face, both physically and financially. ...
Dosage Flexibility of Liquid Hypothyroidism Treatment Introduced for Patients and Clinicians
Americans diagnosed with hypothyroidism and their clinical providers now have access to greater dosage flexibility within levothyroxine therapy, with three new dosage strengths of levothyroxine sodium oral solution now available to treat hypothyroidism. IBSA Pharma markets the drug as Tirosint®-SOL. The unique new dosing options – 37.5, 44 and 62.5 micrograms – are a first...
Continuous Glucose Monitor Developed to Integrate Data Directly into Electronic Health Record
HealthPartners Institute’s International Diabetes Center (IDC) recently developed and piloted a process for incorporating patients’ continuous glucose monitoring (CGM) data directly into the electronic health record (EHR), improving clinician access to glucose information. During a presentation at the American Diabetes Association’s 81st Scientific Sessions, IDC medical director Amy Criego, MD, described this process for integrating...
The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...
